Capricor Therapeutics, Inc. (CAPR) – What Are Researchers Saying About This Stock?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have earned an average rating of “Hold” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $30.25.

Several research firms have recently commented on CAPR. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a research note on Tuesday, July 28th. Oppenheimer reiterated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Finally, JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in the company. Walleye Capital LLC purchased a new stake in shares of Capricor Therapeutics in the 1st quarter worth about $5,397,000. Bank of America Corp DE increased its stake in shares of Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after acquiring an additional 361,664 shares in the last quarter. Creek Drive Management Group LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth about $1,039,000. Montanova Capital LLC lifted its position in Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after acquiring an additional 274,184 shares during the period. Finally, Ally Bridge Group NY LLC purchased a new position in Capricor Therapeutics during the 1st quarter valued at about $3,463,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $6.88 on Wednesday. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37. The firm has a fifty day simple moving average of $7.88 and a two-hundred day simple moving average of $19.93.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, equities research analysts predict that Capricor Therapeutics will post -1.71 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration.